The National Agency for Food and Drug Administration and Control (NAFDAC) has alerted Nigerians, particularly healthcare providers, to be aware of a batch of counterfeit Meronem 1g injection circulating the country.
This was contained in a public alert No. 036/2023, signed by the agency’s Director-General, Prof. Mojisola Adeyeye, and issued to the News Agency of Nigeria (NAN) in Abuja on Tuesday, November 21.
According to Adeyeye, the Marketing Authorization Holder (MAH), Pfizer, reported the incident, as received through a patient notification platform, concerning a suspicious Meronem 1g injection purchase.
The patient noted that the vial content did not dissolve when reconstituted for use and that further visual inspection of the pack was observed.
Further investigations showed that the crimp code did not match the code reported on the production documentation batch of 2A21F11, the semi-finished batch used for 4A21I17.
The D-G said that the production process did not meet Pfizer’s specifications.
“The vial label compares favourably to the purported artwork version.
“Meronem (Meropenem trihydrate injection) is an antibiotic used to treat skin and abdominal (stomach area) infections caused by bacteria and meningitis (infection of the membranes that surround the brain and spinal cord) in adults and children 3 months of age and older.
“The administration of the counterfeit product will pose a high risk to patients as the quality and safety are not guaranteed,” Adeyeye said.
The NAFDAC boss, however, said that healthcare providers and patients were advised to obtain all medical products from authorized or licensed suppliers.
She further called on those in possession of the counterfeit product to seek immediate medical advice from a qualified healthcare professional if they had already used the product or suffered from any adverse after use reactions.
